Award
National Institute of Allergy and Infectious Diseases 5U01AI167786-04
First-in-human study of a potent anti-HBsAg neutralizing antibody
Recipient
Rockefeller University, New York, NY, United States
Award Amount
$808,630.00
Ceiling
$808,630.00
Awarded
February 12, 2026
Identifier
5U01AI167786-04
This award funds a clinical trial to evaluate a potent anti-HBsAg neutralizing antibody for chronic hepatitis B patients on antiviral therapy, aiming to achieve functional cure through immune response enhancement.
Description
A first-in-human dose-escalation study of a long-acting variant of HepB mAb19 in individuals with chronic hepatitis B on antiviral nucleos(t)ide analogue therapy to test safety, tolerability, and efficacy in decreasing circulating HBsAg and enhancing immune responses.